Posted 1 month ago

Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08)

ClinicalTrials.gov ID NCT05215340

Protocol number DS1062- A- U304

Sponsor Daiichi Sankyo